High-Intensity Interval Training (HIIT) has rapidly gained traction across the UK as one of the most efficient workout methods for weight loss and overall fitness. For women navigating the demands of modern life be it careers, family commitments, or personal pursuits, finding time-efficient and effective ways to maintain health is paramount. HIIT emerges as a solution that not only fits into tight schedules but also delivers impressive results.
According to the NHS, approximately 29% of women in England are classified as obese, and an additional 31% are overweight. These statistics underscore a pressing need for accessible, effective weight loss strategies tailored to women's unique physiological and lifestyle needs. This guide delves into how HIIT can be a transformative tool for women aiming to shed pounds, boost their health, and enhance their quality of life.
What is HIIT?
HIIT stands for High-Intensity Interval Training, a workout methodology characterised by short bursts of intense exercise alternated with periods of rest or low-intensity movement. This training style is designed to maximise calorie burn and improve cardiovascular fitness more efficiently than traditional steady-state exercises.
Core Principles of HIIT
Intensity: Engaging in exercises at 80-95% of your maximum heart rate. This level of effort pushes your body out of its comfort zone, leading to significant physiological adaptations.
Intervals: Structured periods of high-intensity activity (typically 20 seconds to 2 minutes) followed by rest or active recovery periods of equal or longer duration.
Duration: HIIT workouts are concise, generally lasting between 15 to 30 minutes, making them ideal for busy schedules.
Variations of HIIT
Understanding different HIIT variations allows you to select a style that aligns with your preferences and fitness level.
Tabata Training: Originating from Japan, this protocol involves 20 seconds of maximum effort followed by 10 seconds of rest, repeated eight times for a total of four minutes. It's highly effective for improving aerobic and anaerobic capacity.
EMOM (Every Minute on the Minute): Perform a specific number of repetitions at the start of every minute. The quicker you complete them, the more rest you have before the next minute begins. This format builds endurance and pacing.
Circuit Training: Rotate through a series of exercises targeting different muscle groups with minimal rest in between. This keeps your heart rate elevated and muscles engaged throughout the session.
Fartlek Training: A Swedish term meaning "speed play," this involves varying your speed and intensity at random intervals during activities like running or cycling.
Each variation offers unique benefits. For instance, Tabata is excellent for those looking to improve speed and power, while circuit training is beneficial for full-body conditioning.
How Can HIIT Help with Weight Loss?
HIIT's effectiveness in weight loss is supported by a growing body of scientific research. It combines cardiovascular and strength training elements, leading to comprehensive fitness improvements.
The Science Behind HIIT's Effectiveness
Increased Calorie Burn
HIIT workouts can burn significantly more calories in a shorter time compared to traditional exercise forms. A research study found that HIIT burns 25-30% more calories than other forms of exercise like weight training, cycling, and running on a treadmill.
One of HIIT's most significant advantages is the EPOC effect, commonly known as the "afterburn." After intense exercise, your body consumes more oxygen to restore itself to its resting state, burning additional calories in the process. This elevated metabolic rate can last for up to 24 hours post-workout, enhancing overall calorie expenditure.
Muscle Building and Metabolism Boost
HIIT stimulates muscle protein synthesis due to the resistance and anaerobic components involved. Building lean muscle mass is crucial because muscle tissue burns more calories at rest than fat tissue. The American Council on Exercise explains that increased muscle mass leads to a higher resting metabolic rate, aiding long-term weight management.
Cardiovascular and Health Benefits
Heart Health Improvement
HIIT has been shown to enhance cardiovascular function by increasing VO2 max—the maximum rate of oxygen consumption measured during incremental exercise. The British Heart Foundation notes that regular HIIT sessions can reduce blood pressure and lower the risk of heart disease.
Blood Sugar Regulation
For women at risk of type 2 diabetes or those with insulin resistance, HIIT can improve insulin sensitivity. A study in Diabetes Care found that HIIT significantly reduced blood glucose levels in participants with type 2 diabetes (Little et al., 2011).
HIIT for Women: Addressing Specific Concerns
While HIIT offers numerous benefits, it's essential to address specific concerns women may have to ensure the training is both safe and effective.
Common Concerns
Intensity Levels
Many women worry that HIIT may be too demanding, especially if they are new to exercise or returning after a hiatus. The high-intensity nature can seem intimidating, but HIIT is adaptable to all fitness levels.
Safety and Risk of Injury
The rapid movements and high-impact exercises in HIIT can increase the risk of injuries if not performed correctly. Concerns about joint health, particularly knees and ankles, are common.
Hormonal Fluctuations
Women's hormonal cycles can affect energy levels, endurance, and strength. Understanding how to adjust workouts during different menstrual phases is crucial.
Modifications for Safety and Comfort
Customising HIIT workouts can mitigate risks and enhance enjoyment.
Beginner-Friendly Adjustments
Lower Impact Options: Replace high-impact moves like jump squats with bodyweight squats.
Reduced Intensity: Start with a 1:2 work-to-rest ratio (e.g., 20 seconds of work, 40 seconds of rest).
Simplified Exercises: Opt for exercises that are easier to perform with correct form.
Exercise Modification Table
Impact of Menstrual Cycle
TheNHS suggests that moderate exercise during menstruation can alleviate cramps and boost mood. However, during the luteal phase (post-ovulation), energy levels may dip. Adjusting HIIT intensity during these times can help maintain consistency without overexertion.
HIIT and PCOS
Polycystic Ovary Syndrome (PCOS) affects approximately 1 in 10 women in the UK, leading to symptoms like weight gain and insulin resistance. According to Verity, a UK-based PCOS charity, incorporating HIIT into exercise routines can improve insulin sensitivity and support weight management. A study in the Journal of Clinical Endocrinology & Metabolism found that HIIT significantly reduced insulin resistance in women with PCOS (Harrison et al., 2012).
Creating a HIIT Workout Routine
Designing a personalised HIIT routine ensures that the workout is effective, enjoyable, and sustainable.
Steps to Build Your Routine
Assess Your Fitness Level
Beginner: New to exercise or returning after a long break.
Intermediate: Regularly active but new to HIIT.
Advanced: Experienced with high-intensity workouts.
Set Realistic Goals
Short-Term: Aim to complete three HIIT sessions per week.
Long-Term: Target a specific weight loss goal or fitness milestone.
MHRA: Safety notices and advice on health products.
NICE Guidelines: Best practices for physical activity interventions.
Conclusion
HIIT stands out as a versatile, efficient, and effective approach to weight loss and overall health improvement for women. By combining intense activity with strategic rest periods, HIIT maximises calorie burn, boosts cardiovascular health, and promotes lean muscle development—all within a time frame that suits busy lifestyles.
Remember, the key to success with HIIT—or any fitness programme—is consistency, personalisation, and listening to your body. Tailor your workouts to your fitness level, adjust intensity as needed, and don't hesitate to seek professional guidance when necessary.
Embrace the journey towards a healthier, more vibrant you. Consider joining fitness communities, both in-person and online, to share experiences, gain support, and stay motivated. Your commitment today paves the way for a healthier tomorrow.
When new medical studies are released, they can feel full of numbers and complex terms. At SheMed, our role is to help you understand what they really mean for you, your health, and your future.
Recently, Novo Nordisk released the results of the STEER study, one of the most significant pieces of research yet on GLP-1 medicines like Wegovy. And the findings show something powerful: Wegovy is not only about weight loss, it’s also about heart health.
The Big Picture: What the STEER Study Looked At
The STEER study explored how GLP-1 medicines affect heart health in people living with Overweight or Obesity and established cardiovascular disease (but without diabetes).
Researchers compared Wegovy (Semaglutide 2.4mg) with Tirzepatide (Mounjaro). They focused on the risk of serious heart problems, what doctors call “major adverse cardiovascular events” (MACE). These include:
Heart attack
Stroke
Death from heart disease
What They Found
The results were striking:
For people who stayed on treatment without big gaps, Wegovy reduced the risk of heart attack, stroke, or cardiovascular death by 57% more than Mounjaro.
When looking at all treated people, even those with breaks in care Wegovy still showed a 29% reduction in these serious events overall.
In short, Wegovy is not only helping people lose weight, it is also showing clear cardiovascular protection, especially when used consistently.
Why This Matters for You
We’ve always known GLP-1 medicines are powerful tools for weight loss, but the STEER study highlights something even bigger: they can also protect your heart. For anyone living with Obesity and cardiovascular disease, this is game-changing.
It also reinforces an important truth - long-term commitment matters most. The people who saw the greatest benefits were those who stayed consistent with their medication. That’s why at SheMed, we design every part of our programme to keep you supported, motivated, and engaged for the long run.
The SheMed Difference: Seeing the Bigger Picture
Medication is only one part of your health journey. At SheMed, we combine Wegovy with wraparound care:
Regular blood tests to track key markers like cholesterol, blood sugar, and liver health.
Weekly check-ins and app reminders to help you stay on track.
Education and content designed specifically for women, covering sleep, hormones, activity, and nutrition.
Proactive Side effect care and support to keep you comfortable and supported as your body adjusts.
This holistic approach matters because weight loss is just one marker of progress. By running blood tests before starting the programme, at 6 months, and 12 months, we can show you the deeper changes happening inside your body, improvements in cholesterol, blood sugar, and overall metabolic health.
It means you’ll see the true value of GLP-1s, not just in how you look or feel, but in the measurable ways your health is improving and your risks are reducing.
Why Wegovy Through SheMed Makes Sense
At SheMed, we’ve worked hard to make Wegovy accessible and affordable. With static, transparent pricing across doses, our members know exactly what they’re paying. That means no hidden surprises and no price hikes as you move up through titration.
When you combine that cost benefit with the evidence from STEER that Wegovy offers not just weight loss but cardiovascular protection the case for choosing Wegovy through SheMed becomes even stronger.
You’re not just investing in weight management; you’re investing in heart health, future health, and a programme designed to keep you safe and supported every step of the way.
The Future of Health With SheMed
The STEER study is a reminder that the story of GLP-1s is still unfolding and it’s about so much more than weight loss. These medicines are changing how we think about obesity, cardiovascular health, and long-term wellbeing.
At SheMed, we’ll continue to keep you informed as new research emerges, but more importantly, we’ll keep showing you the bigger picture through your own results. With every blood test, every milestone, and every step forward, you’ll see how far you’ve come not just in weight, but in health.
Because at SheMed, you’re not just losing weight. You’re gaining health, protecting your future, and building the strongest version of you.
Wegovy has quickly become a key treatment option in obesity management, particularly for adults living with excess weight and health conditions linked to obesity.
With recent price increases for Mounjaro®, another GLP-1 medication, many patients and healthcare providers are now turning to Wegovy as a strong alternative.
Clinical research shows that Wegovy can deliver significant weight loss results, often comparable to those seen with Mounjaro, making it one of the most effective options currently available.
Recent news and clinical trial data reveal that higher doses of Wegovy specifically at 7.2 mg weekly, have led to average weight loss of around 21% in adults with obesity, with approximately one-third of participants achieving a weight loss of 25% or more over 72 weeks. This is notably greater than the 15% average weight loss seen at the standard 2.4 mg dose.
Latest Clinical Data on Higher Doses
The 2025 STEP UP phase 3b trial evaluated semaglutide at both 7.2 mg and 2.4 mg weekly doses versus placebo in people with obesity who did not have diabetes. The results indicated a clear dose-response effect:
Mean weight loss was 21% at 7.2 mg, compared to 17.5% at 2.4 mg, and much lower with placebo.
Specifically, 51% of those on 7.2 mg lost at least 20% of their body weight, and 33% achieved a reduction of 25% or more.
For 2.4 mg, 35% lost 20% or more, and 17% achieved 25% or greater weight loss.
Regulatory and Safety Considerations
Novo Nordisk has announced plans to seek regulatory approval for the higher 7.2 mg dose in the EU and other regions in late 2025.
Safety and tolerability of the 7.2 mg weekly dose were consistent with the known profile of semaglutide, with gastrointestinal side effects remaining most common, except for a low discontinuation rate for adverse effects (about 3%).
These findings extend the potential of Wegovy for people requiring greater degrees of weight loss, emphasising the dose-dependent effect of semaglutide GLP-1 therapy.
Comparing New findings with Mounjaro
At higher doses (7.2 mg), Wegovy has demonstrated weight loss outcomes that closely mirror those achieved with Mounjaro. Clinical data show an average 21% reduction in body weight over 72 weeks with Wegovy, with around half of patients reaching at least 20% weight loss. By comparison, Mounjaro studies report average reductions of up to 22–23% at higher doses over a similar treatment duration. While Wegovy’s 7.2 mg dose remains under regulatory review and is not yet standard practice, these findings highlight that patients considering a switch may be able to achieve results that are highly comparable to those seen with Mounjaro, offering another strong option in pharmacological obesity management.
Head-to-head style snapshot (72-week outcomes)
In conclusion, if you are considering switching from Mounjaro to Wegovy, now is an excellent opportunity. Wegovy offers a highly effective alternative for weight management with similar clinical results, and - importantly - comes at a considerably lower price, especially as Mounjaro prices are set to rise sharply in the UK from September 2025. Choosing Wegovy can help maintain your weight loss goals while making your treatment more affordable.
If you have any questions or need personalised advice about making the switch, please do not hesitate to contact the Shemed support team at support@shemed.com.
References
ClinicalTrials.gov. (2024, December 12). A research study to see how semaglutide helps people with excess weight, lose weight (STEP UP) (NCT05646706). U.S. National Library of Medicine. https://clinicaltrials.gov/study/NCT05646706
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Wadden, T. A. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
American Diabetes Association (ADA). (2025, June). STEP UP trial: Semaglutide 7.2 mg in adults with obesity without type 2 diabetes [Conference presentation]. ADA 85th Scientific Sessions, Chicago, IL. Retrieved from https://diabetesjournals.org/ (poster abstract ePoster 446-P).
Novo Nordisk. (2025, June 9). Semaglutide 7.2 mg shows ~21% weight loss at 72 weeks in STEP UP trial [Press release]. Retrieved from https://www.novonordisk.com/
Subscribe to our Newsletter
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.